Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve‐week, randomized, placebo‐controlled study
- 1 May 1999
- journal article
- clinical trial
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 1 (3) , 165-172
- https://doi.org/10.1046/j.1463-1326.1999.00020.x
Abstract
Aim: Rosiglitazone is the most potent of the thiazolidinediones, a novel class of oral antidiabetic agents that reduce blood glucose levels by sensitizing peripheral tissues to insulin. This study w...Keywords
This publication has 24 references indexed in Scilit:
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.Journal of Clinical Investigation, 1997
- The Peroxisome Proliferator‐activated Receptors: Ligands and ActivatorsaAnnals of the New York Academy of Sciences, 1996
- Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patientsDiabetologia, 1996
- Treatment with the Thiazolidinedione (BRL 49653) Decreases Insulin Resistance in Obese Zucker HindlimbHormone and Metabolic Research, 1995
- End-Stage Renal Disease Attributable to Diabetes MellitusAnnals of Internal Medicine, 1994
- [[.omega.-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agentsJournal of Medicinal Chemistry, 1994
- A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the ratDiabetes, 1994
- Pathogenesis of NIDDM: A Balanced OverviewDiabetes Care, 1992